{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:44Z","timestamp":1787020484972,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2020R1C1C1007431"],"award-info":[{"award-number":["2020R1C1C1007431"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2025-00514590"],"award-info":[{"award-number":["RS-2025-00514590"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Korean Fund for Regenerative Medicine","award":["21A0404L1"],"award-info":[{"award-number":["21A0404L1"]}]},{"name":"KRIBB Research Initiative Program"},{"name":"University of Science and Technology","award":["2024YS18"],"award-info":[{"award-number":["2024YS18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gemcitabine (GEM) is used as a first-line therapy for patients diagnosed with any stage of pancreatic cancer (PC); however, patient survival is poor because of GEM resistance. Thus, new approaches to overcome GEM resistance in PC are urgently needed. Here, we aimed to establish an in vivo drug-resistant PC model and identify genes involved in GEM resistance. We focused on one of these factors, CITED4, and elucidated its mechanisms of action in GEM resistance in PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      L3.6pl, a GEM-sensitive PC cell line, was orthotopically injected into the pancreas of BALB\/c nude mice to establish a GEM-resistant PC animal model. Transcriptomic data from control or GEM-resistant tumor-derived cells were analyzed. GEM resistance was evaluated using cell viability, clonogenicity, and apoptosis assays. An apoptosis array was used to identify genes downstream of\n                      <jats:italic>CITED4<\/jats:italic>\n                      . A\n                      <jats:italic>CITED4<\/jats:italic>\n                      knockout-mediated GEM sensitivity assay was performed in an orthotopic xenograft mouse model using PANC-1 cells, which are GEM-resistant cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From the RNA sequencing data of isolated GEM-resistant PC cells and The Cancer Genome Atlas dataset, 15 GEM resistance-related genes were found to be upregulated, including\n                      <jats:italic>CITED4<\/jats:italic>\n                      , the gene encoding a type of CBP\/p300-interacting transactivator implicated in several cancers.\n                      <jats:italic>CITED4<\/jats:italic>\n                      knockdown in drug-resistant cells reduced cell proliferation and migration but increased apoptosis. To identify the molecular mechanism underlying CITED4-mediated induction of GEM resistance, alterations in Baculoviral IAP Repeat Containing 2 (BIRC2) levels were observed using an apoptosis array.\n                      <jats:italic>BIRC2<\/jats:italic>\n                      expression was downregulated following\n                      <jats:italic>CITED4<\/jats:italic>\n                      knockdown in GEM-resistant PC cell lines. Furthermore, chromatin immunoprecipitation and promoter assays showed that\n                      <jats:italic>BIRC2<\/jats:italic>\n                      was directly regulated by\n                      <jats:italic>CITED4<\/jats:italic>\n                      . Consistent with the\n                      <jats:italic>CITED<\/jats:italic>\n                      -knockdown experiments, silencing of\n                      <jats:italic>BIRC2<\/jats:italic>\n                      increased the sensitivity of L3.6pl-GEM-resistant and PANC-1 cell lines to GEM. Furthermore,\n                      <jats:italic>CITED4<\/jats:italic>\n                      knockout using the CRISPR-Cas9 system in PANC-1 cells increased the sensitivity to GEM in orthotopic mice. Moreover, elevated CITED4 and BIRC2 expression levels were associated with poorer outcomes in human PC clinical samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, these results indicate that CITED4 regulates GEM resistance via inhibition of apoptosis by upregulating BIRC2 expression in PC cells. Therefore, CITED4 may serve as a valuable diagnostic marker and therapeutic target for GEM-resistant PC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-025-01140-y","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:41:17Z","timestamp":1747644077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer"],"prefix":"10.1186","volume":"32","author":[{"given":"Eun-Jeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Seong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taesang","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seung","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-5898","authenticated-orcid":false,"given":"Tae-Su","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Kug","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"4","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/MCG.0000000000001688","volume":"57","author":"PA Twohig","year":"2023","unstructured":"Twohig PA, Butt MU, Gardner TB, Chahal P, Sandhu DS. Racial and gender disparities among obese patients with pancreatic cancer: a trend analysis in the United States. J Clin Gastroenterol. 2023;57(4):410\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884\u201395.","journal-title":"J Invest Surg"},{"issue":"1","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbcan.2018.04.011","volume":"1870","author":"DE Biancur","year":"2018","unstructured":"Biancur DE, Kimmelman AC. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer. 2018;1870(1):67\u201375.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40\u2013106.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","volume":"189","author":"SF Sener","year":"1999","unstructured":"Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985\u20131995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1\u20137.","journal-title":"J Am Coll Surg"},{"issue":"29","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","volume":"288","author":"S Arora","year":"2013","unstructured":"Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J Biol Chem. 2013;288(29):21197\u2013207.","journal-title":"J Biol Chem"},{"issue":"2","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.canlet.2014.02.015","volume":"347","author":"SK Srivastava","year":"2014","unstructured":"Srivastava SK, Arora S, Singh S, Bhardwaj A, Averett C, Singh AP. MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett. 2014;347(2):167\u201374.","journal-title":"Cancer Lett"},{"issue":"10","key":"1140_CR10","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1097\/JS9.0000000000002086","volume":"110","author":"K Conlon","year":"2024","unstructured":"Conlon K, Coppola R. Updates on pancreatic cancer treatment\u2014invited special issue. Int J Surg. 2024;110(10):6049\u201351.","journal-title":"Int J Surg"},{"issue":"5","key":"1140_CR11","doi-asserted-by":"publisher","first-page":"101056","DOI":"10.1016\/j.tranon.2021.101056","volume":"14","author":"M Mollaei","year":"2021","unstructured":"Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol. 2021;14(5):101056\u201382.","journal-title":"Transl Oncol"},{"issue":"11","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1039\/D4MD00165F","volume":"15","author":"J Cheng","year":"2024","unstructured":"Cheng J, Zhu T, Liu S, Zhou J, Wang X, Liu G. Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer. RSC Med Chem. 2024;15(11):3853\u201361.","journal-title":"RSC Med Chem"},{"issue":"30","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NM Cerqueira","year":"2007","unstructured":"Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507\u201315.","journal-title":"Chemistry"},{"issue":"1","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/A:1006559901771","volume":"16","author":"BS Zhou","year":"1998","unstructured":"Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998;16(1):43\u20139.","journal-title":"Clin Exp Metastasis"},{"key":"1140_CR15","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/597098","volume":"2010","author":"J Zhou","year":"2010","unstructured":"Zhou J, Oliveira P, Li X, Chen Z, Bepler G. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids. 2010;2010: 597098.","journal-title":"J Nucleic Acids"},{"issue":"11","key":"1140_CR16","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-09-0371","volume":"69","author":"CL Costantino","year":"2009","unstructured":"Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 2009;69(11):4567\u201372.","journal-title":"Cancer Res"},{"issue":"1","key":"1140_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3892\/or.2015.3969","volume":"27","author":"M Chen","year":"2012","unstructured":"Chen M, Xue X, Wang F, An Y, Tang D, Xu Y, et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol Rep. 2012;27(1):265\u20139.","journal-title":"Oncol Rep"},{"key":"1140_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fphar.2014.00163","volume":"5","author":"L Zinzi","year":"2014","unstructured":"Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M, Colabufo NA. ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front Pharmacol. 2014;5:163.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1140_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.canlet.2012.11.005","volume":"329","author":"Y An","year":"2013","unstructured":"An Y, Cai B, Chen J, Lv N, Yao J, Xue X, et al. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett. 2013;329(2):228\u201335.","journal-title":"Cancer Lett"},{"issue":"1","key":"1140_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1593\/neo.121312","volume":"15","author":"H Griesmann","year":"2013","unstructured":"Griesmann H, Ripka S, Pralle M, Ellenrieder V, Baumgart S, Buchholz M, et al. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia. 2013;15(1):11\u201322.","journal-title":"Neoplasia"},{"issue":"6","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-08-4312","volume":"69","author":"Z Wang","year":"2009","unstructured":"Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400\u20137.","journal-title":"Cancer Res"},{"issue":"21","key":"1140_CR22","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1038\/onc.2016.465","volume":"36","author":"CH Hsieh","year":"2017","unstructured":"Hsieh CH, Chou YT, Kuo MH, Tsai HP, Chang JL, Wu CW. A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer. Oncogene. 2017;36(21):2946\u201356.","journal-title":"Oncogene"},{"issue":"1","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00432-015-2011-5","volume":"142","author":"MA Rogers","year":"2016","unstructured":"Rogers MA, Kalter V, Marcias G, Zapatka M, Barbus S, Lichter P. CITED4 gene silencing in colorectal cancer cells modulates adherens\/tight junction gene expression and reduces cell proliferation. J Cancer Res Clin Oncol. 2016;142(1):225\u201337.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1140_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-011-1657-1","volume":"130","author":"KT Huang","year":"2011","unstructured":"Huang KT, Takano EA, Mikeska T, Byrne DJ, Dobrovic A, Fox SB. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Res Treat. 2011;130(1):319\u201329.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1140_CR25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/1759-7714.13831","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang Y, Sha Y, Zhang B, Zhang R, Zhang H, et al. CITED4 enhances the metastatic potential of lung adenocarcinoma. Thorac Cancer. 2021;12(9):1291\u2013302.","journal-title":"Thorac Cancer"},{"issue":"5","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s12276-023-00987-1","volume":"55","author":"K Kim","year":"2023","unstructured":"Kim K, Ryu TY, Jung E, Han TS, Lee J, Kim SK, et al. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis. Exp Mol Med. 2023;55(5):952\u201364.","journal-title":"Exp Mol Med"},{"key":"1140_CR27","doi-asserted-by":"crossref","unstructured":"Lee YJ, Jung E, Choi J, Hwang JS, Jeong EJ, Roh Y, et al. The EDN1\/EDNRA\/beta\u2011arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation. Int J Oncol. 2023;62(1).","DOI":"10.3892\/ijo.2022.5461"},{"issue":"11","key":"1140_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.14348\/molcells.2021.0169","volume":"44","author":"J Lee","year":"2021","unstructured":"Lee J, Kim Y, Jin S, Yoo H, Jeong S, Jeong E, et al. Q-omics: smart software for assisting oncology and cancer research. Mol Cells. 2021;44(11):843\u201350.","journal-title":"Mol Cells"},{"issue":"W1","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"W561","DOI":"10.1093\/nar\/gkz445","volume":"47","author":"A Koch","year":"2019","unstructured":"Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T. MEXPRESS update 2019. Nucleic Acids Res. 2019;47(W1):W561\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1140_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13072-019-0316-3","volume":"12","author":"Y Li","year":"2019","unstructured":"Li Y, Ge D, Lu C. The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019;12(1):71.","journal-title":"Epigenetics Chromatin"},{"issue":"17","key":"1140_CR32","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-11-1185","volume":"17","author":"C Carbone","year":"2011","unstructured":"Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 2011;17(17):5822\u201332.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1140_CR33","doi-asserted-by":"publisher","first-page":"8559","DOI":"10.1074\/jbc.M110850200","volume":"277","author":"J Braganca","year":"2002","unstructured":"Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC, et al. Human CREB-binding protein\/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem. 2002;277(10):8559\u201365.","journal-title":"J Biol Chem"},{"issue":"17","key":"1140_CR34","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1158\/0008-5472.CAN-04-0708","volume":"64","author":"SB Fox","year":"2004","unstructured":"Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC, et al. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res. 2004;64(17):6075\u201381.","journal-title":"Cancer Res"},{"issue":"6","key":"1140_CR35","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3892\/ijmm.2012.1138","volume":"30","author":"SG Gray","year":"2012","unstructured":"Gray SG, Baird AM, O\u2019Kelly F, Nikolaidis G, Almgren M, Meunier A, et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int J Mol Med. 2012;30(6):1505\u201311.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1140_CR36","doi-asserted-by":"publisher","first-page":"6826","DOI":"10.1038\/s41598-025-90997-y","volume":"15","author":"P Menapree","year":"2025","unstructured":"Menapree P, Duangthim N, Sae-Fung A, Sonkaew S, Jitkaew S. CDK4\/6 inhibitors upregulate cIAP1\/2, and Smac mimetic LCL161 enhances their antitumor effects in cholangiocarcinoma cells. Sci Rep. 2025;15(1):6826\u201342.","journal-title":"Sci Rep"},{"issue":"7","key":"1140_CR37","doi-asserted-by":"publisher","first-page":"107463","DOI":"10.1016\/j.jbc.2024.107463","volume":"300","author":"B Gao","year":"2024","unstructured":"Gao B, Qiao Y, Zhu S, Yang N, Zou SS, Liu YJ, et al. USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells. J Biol Chem. 2024;300(7):107463\u201377.","journal-title":"J Biol Chem"},{"issue":"4","key":"1140_CR38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s12026-024-09491-8","volume":"72","author":"X Liu","year":"2024","unstructured":"Liu X, Li Y, Zhang W, Gao N, Chen J, Xiao C, et al. Inhibition of cIAP1\/2 reduces RIPK1 phosphorylation in pulmonary endothelial cells and alleviate sepsis-induced lung injury and inflammatory response. Immunol Res. 2024;72(4):841\u201350.","journal-title":"Immunol Res"},{"issue":"2","key":"1140_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.molcel.2008.03.008","volume":"30","author":"SM Srinivasula","year":"2008","unstructured":"Srinivasula SM, Ashwell JD. IAPs: what\u2019s in a name? Mol Cell. 2008;30(2):123\u201335.","journal-title":"Mol Cell"},{"issue":"2","key":"1140_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41419-023-05632-3","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Wei Y, Liu Y, Wei J, Zhou X, Duan Y, et al. BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma. Cell Death Dis. 2023;14(2):121\u201335.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1140_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21873\/cgp.20344","volume":"19","author":"MK Lee","year":"2022","unstructured":"Lee MK, Noh JK, Woo SR, Kong M, Lee YC, Lee JW, et al. Prognostic significance of the BIRC2-BIRC3 gene signature in head and neck squamous cell carcinoma. Cancer Genomics Proteomics. 2022;19(5):591\u2013605.","journal-title":"Cancer Genomics Proteomics"},{"issue":"8","key":"1140_CR42","doi-asserted-by":"publisher","first-page":"108073","DOI":"10.1016\/j.celrep.2020.108073","volume":"32","author":"D Samanta","year":"2020","unstructured":"Samanta D, Huang TY, Shah R, Yang Y, Pan F, Semenza GL. BIRC2 expression impairs anti-cancer immunity and immunotherapy efficacy. Cell Rep. 2020;32(8):108073\u201390.","journal-title":"Cell Rep"},{"key":"1140_CR43","doi-asserted-by":"crossref","unstructured":"Su W, Jiang X, Chen M, Huang M, Tang N, Wang X, et al. cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro. Biosci Rep. 2019;39(4):BSR20182266-BSR76.","DOI":"10.1042\/BSR20182266"},{"issue":"3","key":"1140_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3727\/096504015X14298122915664","volume":"22","author":"H Jin","year":"2014","unstructured":"Jin H, Dong YY, Zhang H, Cui Y, Xie K, Lou G. shRNA depletion of cIAP1 sensitizes human ovarian cancer cells to anticancer agent-induced apoptosis. Oncol Res. 2014;22(3):167\u201376.","journal-title":"Oncol Res"},{"issue":"20","key":"1140_CR45","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.3390\/ijms222011020","volume":"22","author":"CY Lin","year":"2021","unstructured":"Lin CY, Wang CC, Wu RC, Yang LY, Chang CB, Pan YB, et al. Inhibition of BIRC2 sensitizes alpha7-HPV-related cervical squamous cell carcinoma to chemotherapy. Int J Mol Sci. 2021;22(20):11020\u201337.","journal-title":"Int J Mol Sci"},{"issue":"29","key":"1140_CR46","doi-asserted-by":"publisher","first-page":"26895","DOI":"10.18632\/oncotarget.4822","volume":"6","author":"JH Moon","year":"2015","unstructured":"Moon JH, Shin JS, Hong SW, Jung SA, Hwang IY, Kim JH, et al. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer. Oncotarget. 2015;6(29):26895\u2013908.","journal-title":"Oncotarget"},{"issue":"6","key":"1140_CR47","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1007\/s10637-020-00956-9","volume":"38","author":"SW Hong","year":"2020","unstructured":"Hong SW, Shin JS, Moon JH, Jung SA, Koh DI, Ryu Y, et al. Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells. Invest New Drugs. 2020;38(6):1696\u2013706.","journal-title":"Invest New Drugs"},{"key":"1140_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fonc.2014.00197","volume":"4","author":"P Obexer","year":"2014","unstructured":"Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197\u2013206.","journal-title":"Front Oncol"},{"issue":"1","key":"1140_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/cancers3010241","volume":"3","author":"S Fulda","year":"2011","unstructured":"Fulda S. Targeting apoptosis signaling in pancreatic cancer. Cancers (Basel). 2011;3(1):241\u201351.","journal-title":"Cancers (Basel)"},{"issue":"11 Pt 1","key":"1140_CR50","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/1078-0432.CCR-06-0817","volume":"12","author":"HH Cheung","year":"2006","unstructured":"Cheung HH, LaCasse EC, Korneluk RG. X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment. Clin Cancer Res. 2006;12(11 Pt 1):3238\u201342.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1140_CR51","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41419-024-07324-y","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S, He Z, Cai K, Zhang Y, Zhu H, Pang C, et al. TRIM59\/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway. Cell Death Dis. 2024;15(12):932.","journal-title":"Cell Death Dis"},{"issue":"10","key":"1140_CR52","doi-asserted-by":"publisher","first-page":"6868","DOI":"10.1002\/jcp.30346","volume":"236","author":"M Shang","year":"2021","unstructured":"Shang M, Weng L, Xu G, Wu S, Liu B, Yin X, et al. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N\/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. J Cell Physiol. 2021;236(10):6868\u201383.","journal-title":"J Cell Physiol"},{"key":"1140_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.682131","volume":"9","author":"P Chen","year":"2021","unstructured":"Chen P, He Z, Wang J, Xu J, Jiang X, Chen Y, et al. Hypoxia-induced ZWINT mediates pancreatic cancer proliferation by interacting With p53\/p21. Front Cell Dev Biol. 2021;9: 682131.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"1140_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/156800910791190229","volume":"10","author":"AS Azmi","year":"2010","unstructured":"Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010;10(3):319\u201331.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01140-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:03:18Z","timestamp":1747648998000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-025-01140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01140-y","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Public Institutional Review Board of the Ministry of Health and Welfare (P01-202105-31-011). The animal protocol was approved by the Committee on Animal Experimentation of the Korea Research Institute of Bioscience and Biotechnology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}